Back to top

biotechnology: Archive

Benjamin Rains

Here's How to Find Cheap Stocks Under $10 to Buy for December

Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond...

MGNXPositive Net Change NINEPositive Net Change

Zacks Equity Research

CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug

CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.

BIIBNegative Net Change GILDPositive Net Change SLDBNegative Net Change CINCNegative Net Change

Zacks Equity Research

Gilead (GILD), RCUS Announce Positive Data From NSCLC Study

Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).

BIIBNegative Net Change GILDPositive Net Change SLDBNegative Net Change RCUSPositive Net Change

Zacks Equity Research

Incyte (INCY) Outperforms YTD: Will the Momentum Continue?

Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.

NVSNegative Net Change LLYNegative Net Change INCYNegative Net Change SNDXNegative Net Change

Zacks Equity Research

Regeneron (REGN) Outperforms YTD: What's in Store for 2023?

Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.

REGNNegative Net Change SNYPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update

Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.

REGNNegative Net Change CTMXNegative Net Change APLSNegative Net Change INMNegative Net Change

Zacks Equity Research

Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.

REGNNegative Net Change SNYPositive Net Change BIIBNegative Net Change SNDXNegative Net Change

Zacks Equity Research

Prothena (PRTA) Earns Milestone Payment From Novo Nordisk

Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.

BMYNegative Net Change NVOPositive Net Change PRTAPositive Net Change